GLAUKOS CORPRTN

 GKOSのチャート


 GKOSの企業情報

symbol GKOS
会社名 Glaukos Corp (GLAUKOS CORPRTN)
分野(sector)   
産業(industry)   
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 グラウコス(Glaukos Corporation)は眼科医療技術会社である。同社は緑内障の治療用製品の開発・商品化を行う。同社はマイクロ侵襲性緑内障手術(MIGS)装置であるiStentを提供する。iStentは、白内障手術中に作られた小さな角膜切開部を通って挿入され、房水を集めて血流に戻す循環チャネルであるシュレム管に配置されたマイクロバイパスステントである。同社はiStent Inject、iStent Supra、iDoseの3つの追加パイプライン製品を開発する。iStent Injectには、自動注入インサータにプリロードされた2つのステントが含まれる。iStent Supraは、目の中の代替排水スペースにアクセスするように設計される。iDoseは、緑内障患者の眼内圧を低下させるために治療レベルの薬物を長期間にわたって連続的に送達するために眼に埋め込まれるように設計された薬物送達システムである。  グロコスは米国の眼科医療機器メ―カ―。失明の一因である緑内障の治療のための製品や技術の商業化に焦点を当てる。同社はMIGS(超低侵襲な緑内障手術)のパイオニア。主要製品は顕微手術に使用されるチタン製極小管(マイクロバイパス・デバイス)の「iStent」で、FDAに認可されている。本社はカリフォルニア州。  Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
本社所在地 229 Avenida Fabricante San Clemente CA 92672 USA
代表者氏名 William J. Link
代表者役職名 Independent Chairman of the Board
電話番号 +1 949-367-9600
設立年月日 35977
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 437人
url www.glaukos.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -6.73800
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 2825.00300
売上高 (百万ドル) 181.27800
企業価値(EV) (百万ドル) 2684.51500
当期純利益 (百万ドル) -12.95100
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Glaukos Corp revenues increased 14% to $181.3M. Net loss increased from $92K to $13M. Revenues reflect International segment increase of 61% to $29.6M United States segment increase of 8% to $151.7M. Higher net loss reflects Selling general and administrative increase of 20% to $99.7M (expense) Research and development increase of 27% to $44.5M (expense).

 GKOSのテクニカル分析


 GKOSのニュース

   Minimally Invasive Glaucoma Surgery Market Survey Report Discloses Strategy 2027 Roadmap, Key Players -Ziemer Ophthalmic Systems AG, and Glaukos Corporation  2021/08/24 13:13:55 OpenPR
New York, United States: The report on the Minimally Invasive Glaucoma Surgery MARKET market crafted effectively and efficiently by our research wizards at Decisive Markets Insights encompasses all the essentialities of market growth throughout the prevised period of 2021-2027. We
   Ophthalmic Devices Market According to Decisive Markets Insights, Market to grow with speedy growth by 2027, Key Players - Ziemer Ophthalmic Systems AG., Sonomed Escalon, Hoya Group, Gulden Ophthalmics, FCI Ophthalmics, Glaukos Corporation, STAAR Surgic  2021/08/24 11:34:21 OpenPR
The Ophthalmic Devices Market is expected to grow at a CAGR of 6.1 % and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020 The Ophthalmic Devices Market business research report by Decisive Markets Insights
   Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies  2021/08/23 11:00:00 Business Wire
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent® technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for a
   Glaukos Corporation''s (GKOS) CEO Tom Burns on Q2 2021 Results - Earnings Call Transcript  2021/08/08 16:33:05 Seeking Alpha
   Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target  2021/08/06 19:43:18 Business Insider Markets
Glaukos Corporation (NYSE: GKOS ) posted a second-quarter adjusted EPS loss of $(0.11), ahead of $(0.
   Glaucoma Surgery Devices Market Trends, Review, and Forecast by 2026 | Abbott Laboratories, Glaukos Corporation, Alcon, Inc.  2021/06/30 05:42:19 OpenPR
Glaucoma Surgery Devices Market Glaucoma surgery devices are expected to gain momentum in the future since they serve an important role in treating glaucoma. The primary goal of these devices is to attain intraocular pressure stabilisation or decrease (IOP). Because of
   Ophthalmic Equipment Market Growth by Top Manufacturers Bausch + Lomb (US), Carl Zeiss Meditec (Germany), Topcon (Japan), Glaukos Corporation (US)  2021/06/18 19:03:59 Jumbo News
The global ophthalmic equipment market size is projected to reach USD 63.3 billion by 2025 from USD 52.8 billion in 2020, at a CAGR of 3.7% during the forecast period. The market for ophthalmic equipment is driven primarily by the factors such as the rising geriatric population and prevalence of eye diseases, technological advancements in []
   Glaukos gets Australias TGA regulatory approval for PRESERFLO MicroShunt  2021/06/08 11:32:07 Seeking Alpha
   Glaukos Announces Australias TGA Regulatory Approval for PRESERFLO MicroShunt  2021/06/08 00:00:00 BioSpace
Glaukos Corporation announced that the Therapeutic Goods Administration of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery.
   Novel Drugs and Devices to Lower Intraocular Pressure Market - Mati Therapeutics Inc, BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch & Lomb Inc., Sun Pharmaceutical Industries Ltd., Allergan, Alcon Inc., Glaukos Corporation, and Pfizer Inc.  2021/06/07 10:26:23 OpenPR
Novel Drugs and Devices to Lower Intraocular Pressure Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Novel Drugs and Devices to Lower Intraocular Pressure industry overview and then goes into each
   Glaucoma Surgery Devices Market Trends, Review, and Forecast by 2026 | Abbott Laboratories, Glaukos Corporation, Alcon, Inc.  2021/06/30 05:42:19 OpenPR
Glaucoma Surgery Devices Market Glaucoma surgery devices are expected to gain momentum in the future since they serve an important role in treating glaucoma. The primary goal of these devices is to attain intraocular pressure stabilisation or decrease (IOP). Because of
   Ophthalmic Equipment Market Growth by Top Manufacturers Bausch + Lomb (US), Carl Zeiss Meditec (Germany), Topcon (Japan), Glaukos Corporation (US)  2021/06/18 19:03:59 Jumbo News
The global ophthalmic equipment market size is projected to reach USD 63.3 billion by 2025 from USD 52.8 billion in 2020, at a CAGR of 3.7% during the forecast period. The market for ophthalmic equipment is driven primarily by the factors such as the rising geriatric population and prevalence of eye diseases, technological advancements in []
   Glaukos gets Australias TGA regulatory approval for PRESERFLO MicroShunt  2021/06/08 11:32:07 Seeking Alpha
   Glaukos Announces Australias TGA Regulatory Approval for PRESERFLO MicroShunt  2021/06/08 00:00:00 BioSpace
Glaukos Corporation announced that the Therapeutic Goods Administration of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery.
   Novel Drugs and Devices to Lower Intraocular Pressure Market - Mati Therapeutics Inc, BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch & Lomb Inc., Sun Pharmaceutical Industries Ltd., Allergan, Alcon Inc., Glaukos Corporation, and Pfizer Inc.  2021/06/07 10:26:23 OpenPR
Novel Drugs and Devices to Lower Intraocular Pressure Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Novel Drugs and Devices to Lower Intraocular Pressure industry overview and then goes into each

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 GLAUKOS CORPRTN GKOS )

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)